Arch Biopartners Announces Dosing of First Patient in Canada in the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
November 11, 2024 07:30 ET
|
Arch Biopartners
TORONTO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that patient recruitment and dosing have begun in...
Arch Biopartners’ Cilastatin Drug Candidate to Participate in the PONTIAC Phase II Trial Targeting Acute Kidney Injury Caused by Drug Toxins
August 02, 2024 07:20 ET
|
Arch Biopartners
Arch is repurposing cilastatin, a dipeptidase-1 inhibitor, as a new treatment for acute kidney injury (AKI)Cilastatin is particularly well suited to prevent AKI caused by drug toxins due to its unique...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Baxter, Rain, and Danaher, and Encourages Investors to Contact the Firm
September 06, 2023 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Seagate, Baxter, and Rain and Encourages Investors to Contact the Firm
September 01, 2023 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioXcel, Seagate, and Baxter and Encourages Investors to Contact the Firm
August 27, 2023 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, Aug. 27, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Baxter, Danaher, and Syneos and Encourages Investors to Contact the Firm
August 21, 2023 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Baxter, Danaher, and Syneos and Encourages Investors to Contact the Firm
August 16, 2023 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, Aug. 16, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Seagate, Baxter, Danaher, and Syneos and Encourages Investors to Contact the Firm
August 11, 2023 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioXcel, Seagate, Baxter, and Danaher and Encourages Investors to Contact the Firm
August 06, 2023 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, Aug. 06, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
Blood Pressure Cuffs Market Revenues to Reach USD 696.64 million by 2028 - Market Size, Share, Forecasts, & Trends Analysis Report by Mordor Intelligence
August 01, 2023 09:30 ET
|
Mordor Intelligence
Hyderabad, Aug. 01, 2023 (GLOBE NEWSWIRE) -- According to a new market research report titled "Blood Pressure Cuffs Market Report (2023-2028)," the market is estimated at USD 523.28 million in 2023....